Purpose
Previous study has demonstrated that adventitial delivery of lentivirus mediated Vegf-A shRNA (LV-shRNA-Vegf-A, small hairpin RNA that inhibits Vegf-A gene expression) at the time of arteriovenous fistula (AVF) creation increases the lumen vessel area (LVA) of the outflow vein and reduces venous neointimal hyperplasia (VNH). However, the effect of decreasing Vegf-A and improving LVA decreases by 2-weeks as stenosis develops. The aim of the present study was to determine if a second dose of LV-shRNA-Vegf-A could improve LVA and decrease VNH.
Methods
Chronic kidney disease was created in C57BL/6 mice and 28 days later, a AVF was created by connecting right carotid artery to ipsilateral jugular vein. 5×106 plaque forming units of LV-shRNA-Vegf-A or control shRNA was administered to the adventitia of the outflow vein immediately after AVF creation and a second dose of the same treatment fourteen days later. Animals were sacrificed at 21, 28, and 42 days after AVF creation for reverse transcription polymerase chain reaction (RT-PCR) and histomorphometric analyses.
Results
By day 21, there was a 25% increase in the average LVA (day 21: P=0.11), with a decrease in cell proliferation (day 21: P=0.0079, day 28: P=0.28; day 42: P=0.5), decrease in α-smooth muscle cell actin staining (day 21: P<0.0001, day 28: P<0.05; day 42: P=0.59), and decrease in hypoxic stress (day 21: P<0.001, day 28: P=0.28; day 42: P=0.46) in LV versus control shRNA vessels, respectively.
Conclusion
A second dose of LV-shRNA-Vegf-A administration results in a moderate improvement in LVA at day 21.